Rituximab-Associated Progressive Multifocal Leukoencephalopathy: A Twenty-Year Update

Area of Science:

• Neuroimmunology
• Virology
• Oncology

Background:

• Progressive multifocal leukoencephalopathy (PML) is a rare, life-threatening demyelinating disease of the central nervous system.
• PML is caused by the opportunistic reactivation of the John-Cunningham virus (JCV).
• While historically associated with severe immunosuppression, PML has been rarely reported in patients treated with anti-CD20 monoclonal antibodies like rituximab.

Purpose of the Study:

• To investigate the incidence and characteristics of PML in patients treated with rituximab.
• To assess the risk factors associated with PML development in this patient population.
• To understand the clinical presentation and outcomes of rituximab-associated PML.

Main Methods:

• Systematic review of published literature on PML cases in rituximab-treated patients.
• Analysis of patient demographics, underlying conditions, rituximab treatment protocols, and PML diagnosis.
• Evaluation of clinical outcomes, including neurological status and survival rates.

Main Results:

• PML is a rare but serious adverse event associated with rituximab therapy.
• The incidence of PML appears to be low, but the risk is present across various indications for rituximab use.
• Clinical presentations and outcomes vary, highlighting the importance of early diagnosis and management.

Conclusions:

• Rituximab treatment carries a rare risk of PML, necessitating vigilance among clinicians.
• Further research is needed to fully elucidate the mechanisms and optimize preventative strategies for PML in patients receiving B-cell depleting therapies.
• Awareness of PML symptoms and prompt diagnostic workup are crucial for affected individuals.